These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 35785207)
1. Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience. Xu H; Han Y; Wu Y; Wang Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Ma F; Xu B; Wang J Front Oncol; 2022; 12():906011. PubMed ID: 35785207 [TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression]. Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134 [TBL] [Abstract][Full Text] [Related]
3. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis. Ergun Y; Ucar G; Akagunduz B Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351 [TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study. Sun T; Wang T; Li X; Wang H; Mao Y Front Oncol; 2023; 13():1148228. PubMed ID: 37409261 [TBL] [Abstract][Full Text] [Related]
5. Survival differences between HER2-0 and HER2-low-expressing breast cancer - A meta-analysis of early breast cancer patients. Yang C; Zhang X; Chen Y; Li P; Zhang J; Xu A; Huang N; Liang M; Chen Y; Wang K Crit Rev Oncol Hematol; 2023 May; 185():103962. PubMed ID: 36921780 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis. Molinelli C; Jacobs F; Agostinetto E; Nader-Marta G; Ceppi M; Bruzzone M; Blondeaux E; Schettini F; Prat A; Viale G; Del Mastro L; Lambertini M; de Azambuja E ESMO Open; 2023 Aug; 8(4):101592. PubMed ID: 37413762 [TBL] [Abstract][Full Text] [Related]
7. Association between human epidermal growth factor receptor 2 status, namely low and zero expression, and prognosis in hormone receptor-positive breast cancer: a single-center retrospective study. Hara Y; Yano H; Ishida Y; Iwasaki K; Yamaguchi R Transl Cancer Res; 2024 Apr; 13(4):1773-1785. PubMed ID: 38737680 [TBL] [Abstract][Full Text] [Related]
8. In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. Li Y; Abudureheiyimu N; Mo H; Guan X; Lin S; Wang Z; Chen Y; Chen S; Li Q; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B Front Oncol; 2021; 11():774577. PubMed ID: 35111669 [TBL] [Abstract][Full Text] [Related]
9. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study. Liu CG; Li YF; Ma TY; Lv M; Lv ZD; Wang YY; Liu XP; Mao Y; Wang HB Front Oncol; 2023; 13():1130734. PubMed ID: 37064133 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Yang M; Sun J; Liu L; Kong X; Lin D; Zhou H; Gao J Sci Rep; 2023 Jul; 13(1):12382. PubMed ID: 37524746 [TBL] [Abstract][Full Text] [Related]
12. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer. Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052 [TBL] [Abstract][Full Text] [Related]
13. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy. Yang X; Rao J; Yang W; Shui R Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and prognosis of patients with HER2-low breast cancer. Yang X; Li Y; Lu X; Ren X; Hua B BMC Cancer; 2023 Sep; 23(1):914. PubMed ID: 37770874 [TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375 [TBL] [Abstract][Full Text] [Related]
17. New insights into HER2-low breast cancer brain metastasis: A retrospective analysis. Xu H; Wang Y; Li L; Han Y; Wu Y; Sa Q; Xu B; Wang J Breast; 2024 Feb; 73():103669. PubMed ID: 38176304 [TBL] [Abstract][Full Text] [Related]
18. The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis. Tang Y; Shen G; Xin Y; Li Z; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J Ther Adv Med Oncol; 2023; 15():17588359231156669. PubMed ID: 36872948 [TBL] [Abstract][Full Text] [Related]
19. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399 [TBL] [Abstract][Full Text] [Related]
20. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. Jin J; Li B; Cao J; Li T; Zhang J; Cao J; Zhao M; Wang L; Wang B; Tao Z; Hu X J Transl Med; 2023 Jun; 21(1):360. PubMed ID: 37264417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]